Increase in acceptance of the International Normalized Ratio (INR) for the management of oral anticoagulant therapy;Zunehmende akzeptanz der Internationalen Normalisierten Ratio (INR) als uberwachungsparameter der oralen antikoagulantientherapie in Deutschland

Zeitschrift fur Kardiologie

Volumn 87, Issue 10, 1998, Pages 837-843

  Horstkotte, D ^a   Bergemann, R ^b   Oelert, H ^c   Schulte, H D ^d   Laas, J ^e   Zerkowski, H R ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Inst for Medical Outcome Research   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Gefaßerkrankungen der Herz   (Germany)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cardioembolism; GELIA; Heart valve replacement; International Normalized Ratio (INR); Oral anticoagulation

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULATION; ARTICLE; DATA ANALYSIS; DRUG EFFICACY; EMBOLISM; FEMALE; GERMANY; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; GERMANY; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POSTOPERATIVE COMPLICATIONS; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; SWITZERLAND;

EID: 0031738219     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920050239     Document Type: Article

References (18)

1. Bodnar E, Horstkotte O (1993) Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 2:287-290
2. British Society of Haematology, British Committee for Standards in Haematology, Haemostasis and thrombosis task forces (1990) Guidelines on oral anticoagulation, 2nd edn. J Clin Pathol 43:177-183
3. Broeckmans AW, Loeliger EA (1986) High complication and failure rates of anticoagulation therapy are avoidable. Z Kardiol (Suppl 2):298-301
4. Bussey HI, Force RW, BiancoTM, Leonard AD (1992) Reliance on prothrombin time ratios causes significant errors in anticoagulant therapy. Arch Intern Med 152: 278-282
5. Conley CL, Morse WI (1948) Thromboplastie factors in the estimation of prothrombin concentration. M J Med Sci 215: 158-169
6. Dalen JE, Hirsh J (1980) American College of Chest Physicians and the National Heart, Lung and Blood Institute National Conference on Antithrombotic Therapy. Arch Intern Med 146:462-472
7. Eckmann MH, Levine HJ, Pauker SG (1993) Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 329:696-702
8. Gohlke-Bärwolf C, Acar J, Oakley C, Butchart E, Burckhardt D, Bodnar E, Hall R, Delahaye JP, Horstkotte D, Kremer R, Krayenbühl HP, Krzeminska-Pakula M, Samama M (1995) Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 16/10:1320-1330
9. Horstkotte D, Bergemann R, Althaus U, Babin-Ebell J, Chares M, Dahm M, Eigel P, Elert O, Emmrich K, Geiger AW, Hacker R, Haverich A, Hellberg K, Hutschenreiter W, Kirchhoff PG, Konertz W, Laas J, Laczkovics A, Minale C, Oelert H, Polonius MJ, Reidemeister C, Scheid HH, Schubel B, Schulte HD, Siclari F, Torka M, Ursinus W, Warnke H (1993) German Experience with Low Intensity Anticoagulation (GELIA): Protocol of a Multi-Center Randomized Prospective Study with the St. Jude Medical Valve. J Heart Valve Dis 2: 411-419
10. Horstkotte D, Schulte HD, Bircks W, Strauer BE (1993) Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 years follow-up of patients with St. Jude Medical prostheses. J Heart Valve Dis 2:291-301
11. Horstkotte D, Hohnloser S, Keller F, Kolde HJ, Müller-Beißenhirtz W, Taborski U, Webering F (1994) Empfehlung zur Einführung der Internationalen Normalisierten Ratio (INR) als objektives Maß für die Intensität einer oralen Antikoagulantien-Therapie. Z Kardiol 83:676-680
12. Horstkotte D, Schulte HD, Bircks W, Strauer BE (1994) Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 107: 1136-1145
13. Karnofsky DA, Burchenai JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Mac Leod CM (ed) Symposium held at New York Academy of Medicine. Columbia University Press: 191-205
14. Kirkwood TBL (1983) Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemostas 49:238-244
15. Levine MN, Raskob G, Landefeld S, Hirsh J (1995) Hemorrhagic complications of anticoagulant treatment. Chest 108:276S-290S
16. Loeliger EA, Poller L, Samama M, Thomson JM, van den Besselaar AMHP, Vermylen J, Verstraete M (1985) Questions and answers on prothombin time standardisation in oral anticoagulant control. Thromb Haemostas 54:515-517
17. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman ST, Turpie AGG (1995) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108:371S-379S
18. WHO Expert Committee on Biological Standardization (1983) Requirements for thromboplastins and plasma used to control oral anticoagulation therapy. 33rd Report. Techn Rep Ser 687, Geneve, World Health Organisation:81-105